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Abstract 19 
 20 
Chronic kidney disease is common in the general population and associated with excess 21 
cardiovascular disease (CVD), but kidney function does not feature in current CVD risk prediction 22 
models. We tested three formulae for estimated glomerular filtration rate (eGFR) to determine the 23 
most clinically informative for predicting CVD and mortality.  Using data from 440,526 participants 24 
from UK Biobank, eGFR was calculated using serum creatinine, cystatin C (eGFRcys) and creatinine-25 
cystatin C. Associations of each eGFR with CVD outcome and mortality were compared using Cox 26 
models adjusting for atherosclerotic risk factors (per relevant risk scores), and predictive utility was 27 
determined by the C-statistic and categorical Net Reclassification Index.  We show that eGFRcys is 28 
most strongly associated with CVD and mortality, and along with albuminuria adds predictive 29 
discrimination to current CVD risk scores, whilst traditional creatinine-based measures are weakly 30 
associated with risk. Clinicians should consider measuring eGFRcys as part of cardiovascular risk 31 
assessment.   32 
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Introduction 33 
 34 
Chronic kidney disease (CKD), characterized by gradual loss of kidney function over time, is 35 
associated with progression to end-stage kidney disease (ESKD) and is an indicator for renal 36 
replacement therapy, premature cardiovascular disease (CVD) and mortality.  CKD is common in the 37 
general population and affects around 10% of the total population, although estimates of its 38 
prevalence vary.1  Although impaired kidney function indicates patients at risk of future requirement of 39 
renal replacement therapy, the vast majority of patients do not require renal replacement therapy, and 40 
for these the greatest risk of CKD is the excess in cardiovascular risk associated with CKD.2  The 41 
excess CVD risk appears to begin in the relatively early stages of CKD and increases with CKD 42 
stage, especially in CKD stages G3b-5.2–4 The most pronounced effects are seen in those with 43 
advanced CKD or ESKD when the complications specific to CKD - including renal anaemia, 44 
disordered acid-base balance and CKD mineral and bone disorder - are most apparent.5–7 Though the 45 
atherosclerotic risk factors for CVD – such as hypertension, diabetes, dyslipidaemia and smoking – 46 
are prevalent in those with CKD, there is an excess CVD risk seen in CKD beyond that captured by 47 
atherosclerotic risk factors alone.8–12  48 
Large individual patient-level meta-analyses of cohorts combining observational and clinical trial data, 49 
from the CKD Prognosis Consortium, confirm CKD as an additional, independent risk factor for 50 
CVD.13,14 Albuminuria, an important feature of CKD and glomerular damage, is thought to be 51 
associated with increased CVD risk and all-cause mortality. In additional analyses from the CKD 52 
Prognosis Consortium, albuminuria particularly improved CVD risk prediction above current methods 53 
in patients with CKD.15  As far as we are aware, only one risk calculator includes presence of CKD 3-5 54 
as a binary risk factor for CVD risk estimation (QRISK316), whereas other modern calculators in 55 
Europe and the United States do not include CKD as a risk (Systematic Coronary Risk Evaluation 56 
(SCORE)17, American Heart Association/American College of Cardiology (AHA/ACC)18).   57 
The CKD-EPI formula19  to estimate glomerular filtration rate (GFR) has traditionally used serum 58 
creatinine values, adjusted for age, sex and ethnicity, however, in retrospective analyses, CKD-EPI 59 
formulae using cystatin C, either alone or in combination with creatinine, perform better than those 60 
including creatinine alone in estimating GFR20 and in predicting risk of ESKD, CVD and mortality.21   61 
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Cystatin C testing has been available in UK National Health Service laboratories for over 10 years, 62 
and has a number of potential advantages over serum creatinine: it is released by every cell in the 63 
body, is freely filtered at the glomerulus, and is not influenced by body habitus, muscle mass or 64 
gender. It is thus thought to be a more sensitive measure to estimate kidney function.  However, 65 
owing to the costs of the reagents22, cystatin C is around 10 times more expensive than serum 66 
creatinine at £2.50 (USD 3.00) per test compared with £0.25 (USD 0.30) for serum creatinine23.  67 
While this seems a significant additional expense, cystatin C costs about the same or less other 68 
standard tests conducted in patients with CKD, including parathyroid hormone, C-reactive protein and 69 
vitamin D22.  Despite being recommended by the National Institute for Health and Care Excellence 70 
(NICE) in the United Kingdom for confirmatory testing for CKD24, measurement of cystatin C has not 71 
been widely adopted in clinical practice, presumably relating to uncertainty around the added value of 72 
a more expensive biomarker.  73 
UK Biobank is one of the largest prospective population-based cohorts anywhere with extensive 74 
participant phenotyping and sampling of baseline biochemical measures including renal function 75 
(creatinine and cystatin C), albuminuria (urine albumin:creatinine ratio; uACR) and lipids in around 76 
500,000 participants. Using data from UK Biobank, we aimed to determine whether estimated GFR 77 
(eGFR) and albuminuria improves risk prediction for all-cause mortality, and CVD, using serum 78 
creatinine (eGFRcr), cystatin C (eGFRcys) and combined cystatin C-creatinine (eGFRcr-cys) 79 
estimates of GFR. 80 
Results 81 
Demographics of participants 82 
Of the 502,536 participants initially included, 31,283 had missing biochemical data, 260 had prevalent 83 
ESKD, 38 had calculated eGFR (any measure) <15 ml/min/1.73m2 and 30,112 had prior CVD and 84 
were excluded from further analysis: therefore 440,526 participants were included in the models. Over 85 
a median of 8.9 years (Q1-Q3 8.2-9.5 years) of follow-up, 15,469 participants died from any cause, 86 
2552 of which were deaths from CVD (based on European SCORE17). There were 8662 incident fatal 87 
or nonfatal CVD events (based on AHA/ACC definition18) and 336 cases of incident renal replacement 88 
therapy.  89 
 90 
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Participants with lower eGFR measures tended to be older, male, smokers with lower diastolic blood 91 
pressure (DBP), total and high-density lipoprotein (HDL) cholesterol, be on antihypertensive and 92 
statin medications, to report diabetes, and to be in the highest category of uACR (Table 1 and 93 
Supplementary Tables S1 and S2).  eGFRcys provided lower estimates than both eGFRcr and 94 
eGFRcr-cys, resulting in a greater proportion of participants categorised as having CKD G3-5 95 
(eGFRcr 1.9%; eGFRcys 4.0%; eGFRcr-cys 1.3%).   96 
 97 
All eGFR measures were strongly correlated, with the strongest being between eGFRcys and 98 
eGFRcr-cys (r=0.925, p<0.001) and weakest between the eGFRcr and eGFRcys (r=0.599, p<0.001). 99 
The correlation between eGFRcr and eGFRcr-cys was r=0.828 (p<0.001). 100 
Associations between eGFR measures and all-cause mortality, CVD and ESKD outcomes 101 
Unadjusted survival plots for the outcomes of interest across eGFRcr categories are shown in 102 
Extended Data Figures E1-4. The adjusted shape of the associations between each eGFR measure 103 
and all-cause mortality plus both CVD outcomes and ESKD were largely linear and negative (Figure 104 
1). This was most convincing for eGFRcys, with eGFRcr and eGFRcr-cys demonstrating greater 105 
inflections particularly at the lower extremes of eGFR.  For ESKD, all three eGFR displayed an initially 106 
steep negative linear association until around 70 mL/min, and thereafter continued to decrease but at 107 
a lesser gradient (Extended Data Figure E5). Event rates per 100,000 person years for all outcomes 108 
were greater with higher eGFR by all measures (Supplementary data, Table S3).   109 
Adjusted hazard ratios for each eGFR-outcome combination were consistent with lower eGFR being 110 
associated with higher risk of CVD, all-cause mortality, fatal CVD and ESKD (Table 2). For each 111 
outcome, there was a trend that the HR was stronger for measures of eGFR incorporating cystatin C 112 
for each 10ml/min/1.73m2 increase (Table 2), which increased further alongside each 1 standard 113 
deviation increase in eGFR.  The strongest associations (lowest HR per 1 SD difference) were 114 
consistently found for eGFRcys (HRs 0.72, 0.80, 0.66, 0.14, for all-cause mortality, composite CVD, 115 
fatal CVD and ESKD/ renal replacement therapy outcomes, respectively, Table 2).  116 
Prediction of all-cause mortality and CVD with albuminuria  117 
There was an association between decreasing eGFR and increased hazard ratio for all outcomes that 118 
was sustained across uACR groups, though the magnitude of the association was similar in higher 119 
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compared with lower uACR groups (Figure 2 and Supplementary data Table S4). As expected, the 120 
risk of ESKD increases with higher uACR category (Figure 2 and Supplementary data Table S4).  121 
Addition of uACR to atherosclerotic risk factors and eGFR was associated with mortality and CVD 122 
across the full cohort (Supplementary data Tables S5-S7).  Figure 2 shows heat maps for prediction 123 
of all-cause mortality and CVD events using AHA/ACC and SCORE criteria using eGFRcys and 124 
uACR groups.  Addition of albuminuria to eGFRcys and atherosclerotic risk factors did not improve 125 
Net Reclassification Index across 7.5% 10 year risk threshold used in AHA/ACC guidelines18 (Table 126 
3). 127 
Prediction of all-cause mortality and CVD outcomes by eGFR measures 128 
For all-cause mortality, atherosclerotic risk factors (age, sex, ethnicity, systolic blood pressure, 129 
diastolic blood pressure, antihypertensive medications, statin use, smoking, diabetes, total and HDL 130 
cholesterol) yielded a C-statistic of 0.7157 (95% CI 0.7115-0.7200), Figure 3).  Addition of both 131 
eGFRcys and eGFRcr-cys significantly improved discrimination, with the largest improvement seen 132 
with eGFRcys (C-statistic +0.0103, 95% CI 0.0087-0.0121).  Similarly, for the composite fatal/non-133 
fatal CVD outcome (based on AHA/ACC risk score), atherosclerotic risk factors yielded a C-statistic of 134 
0.7387 (95% CI 0.7337-0.7439) which was improved by addition of eGFRcys (C-statistic + 0.0039, 135 
95% CI 0.0025-0.0052). Similarly, and for fatal CVD (based on SCORE), atherosclerotic risk factors 136 
(C-statistic 0.7828, 95% CI 0.7740-0.7917) were improved by addition of the eGFRcys (C-statistic 137 
change +0.0085 (0.0049-0.0122).   138 
For all-cause mortality, and both CVD outcomes, addition of eGFRcr did not improve discrimination.  139 
For the CVD outcome, we tested improvement in risk classification across the 7.5% 10 year risk 140 
threshold for statin therapy used in AHA/ACC guidelines.18 eGFRcr did not improve risk classification, 141 
but measures incorporating eGFRcys did (Table 3).   142 
Subgroup analyses: prediction of all-cause mortality and CVD 143 
Across all subgroups, eGFRcr did not improve prediction of all-cause mortality or either CVD outcome 144 
in addition to atherosclerotic risk factors.  eGFRcys improved prediction of all-cause mortality in all 145 
subgroups (Supplementary Table S5), and prediction of at least one CVD outcome in subgroups 146 
except non-white ethnicity and CKD3b/4 (Supplementary Tables S6 and S7).  In a model 147 
incorporating atherosclerotic risk factors and uACR, eGFRcys improved prediction of mortality across 148 
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all subgroups (Supplementary Table S5); eGFRcys improved prediction of at least one CVD outcome 149 
in subgroups except non-white ethnicity, CKD 3b/4 and BMI 30-35 kg/m2 (Supplementary Tables S6 150 
and S7).  As a sensitivity analysis for data linearity, the performance of each eGFR was tested for all 151 
outcomes in participants with eGFRcr <60ml/min/1.73m2 with consistent conclusions: eGFRcr did not 152 
improve outcome prediction for all-cause mortality or either CVD outcome; addition of eGFRcys most 153 
strongly improved model prediction across all 4 outcomes (Supplementary Table S8).  Across all 154 
models in and in every subgroup, the likelihood ratio test comparing addition of uACR to models 155 
containing atherosclerotic risk factors and eGFR produced p value <0.001. 156 
Discordance analysis 157 
There was absolute discordance >20% between eGFRcr and eGFRcys measurements in 183,867 158 
participants (41.47%).  Baseline characteristics were broadly similar amongst those with discordant 159 
compared with concordant eGFRcr and eGFRcys (Supplementary data Table S9).  Amongst those 160 
with discordant results, eGFRcys remained the marker with the greatest improvement in C-statistic, 161 
adjusted for atherosclerotic risk factors and uACR, across mortality and both CVD outcome measures 162 
(Table 4).  None of the eGFR measures improved prediction over atherosclerotic risk factors and 163 
uACR for ESKD (Table 4), though there were very few ESKD events (n=52) in this subgroup and the 164 
impact of eGFR in this discordant group may be under-estimated. 165 
Discussion 166 
This is the largest prospective cohort study to demonstrate additional reclassification of 167 
cardiovascular risk using eGFRcys, with no added predictive value of traditional eGFRcr. We also 168 
demonstrate eGFRcys to be more strongly associated with future CVD events than eGFRcr for both 169 
CVD outcomes, and this message is consistent across most subgroup analyses. It is not surprising 170 
that baseline kidney function and albuminuria are associated with increased risk of ESKD.  In this 171 
cohort, broadly representative of the general UK population, eGFRcys was more closely associated 172 
with this outcome than eGFRcr – the measure used in current clinical practice.   173 
Estimation of renal function from creatinine has become more reliable since creatinine measurements 174 
were standardised to IDMS-traceable techniques25, however, creatinine remains an imperfect tool to 175 
estimate GFR. Released from the breakdown of muscle tissue, creatinine will be more abundant in 176 
those with extremes of muscle mass, body habitus or dietary habits.  eGFRcr will therefore tend to 177 
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overestimate GFR (and underestimate presence or severity of CKD) in older individuals or those with 178 
less than average muscle mass for their age and is an insensitive marker of kidney impairment in 179 
early disease.  Cystatin C is a small protein produced by all nucleated cells (so is less susceptible to 180 
influence by individual patient characteristics) and is freely filtered at the glomerulus.  Cystatin C is 181 
thought to be a more sensitive blood marker of kidney function than is creatinine, and is not 182 
influenced by muscle mass, age, gender or ethnicity.   183 
Cystatin C, however, is correlated with oxidative stress and inflammation26,27.  Various 184 
cardiometabolic conditions are associated with higher levels of cystatin C; we have adjusted for some 185 
within the current risk prediction tools (diabetes, dyslipidaemia, hypertension).  Patients with other 186 
diagnosed or undiagnosed cardiometabolic conditions, such as thyroid disease, cancer and 187 
glucocorticoid therapy, may have slightly higher levels of cystatin C, confounding the observed effect 188 
of lower eGFRcys on outcome.  This may also explain the difference we observed in the strong 189 
aetiological association between eGFRcys and outcome with modest improvement in risk prediction28.  190 
Observed effects of lower eGFR on cardiovascular risk may be mediated by inadequate adjustment 191 
for atherosclerotic risk factors in patients with CKD in current risk prediction models.  The contribution 192 
of non-traditional CVD risk factors in those with moderate CKD may be less pronounced than 193 
previously thought and use of eGFRcys may serve as a biomarker that better captures risk associated 194 
with other cardiometabolic conditions.  195 
Amongst patients with CKD, CVD risk-reduction relies on three important factors: 1) accurate 196 
diagnosis of CKD; 2) recognition of the elevated risk of CVD; and 3) early identification and treatment 197 
of modifiable risk factors.   198 
In the UK, NICE guidelines recommend considering a cystatin C-based calculator to confirm or refute 199 
a diagnosis of CKD24.  This recommendation is not being undertaken in routine clinical practice and 200 
the diagnostic and prognostic utility of cystatin C in CKD stage G3 is currently being tested in a 201 
prospective study.29 We confirm the observation that reduced kidney function and albuminuria 202 
indicate groups at extremely high risk of need for future renal replacement therapy, as outlined in the 203 
Kidney Failure Risk Equation.30  Our data show that eGFRcys identified a greater proportion of 204 
participants with CKD G3-5 than both eGFRcr and eGFRcr-cys, and is more strongly associated with 205 
clinical outcome than either of the other measures.  On this basis, we suggest that eGFRcys should 206 
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be used for diagnosis of CKD.  This could apply both for confirmation of CKD in patients with eGFRcr 207 
<60ml/min/1.73m2 or for screening for CKD in patients with CVD risk factors, such as diabetes, 208 
hypertension or obesity.   209 
A more accurate diagnosis of CKD should then prompt assessment and treatment of modifiable risk 210 
factors including diabetes mellitus, hypertension, smoking and dyslipidaemia.  The efficacy of statins 211 
in reducing atherosclerotic CVD effects has been demonstrated in randomised clinical trials31,32.  212 
However, the effectiveness of statins in reducing risk of CVD in patients with CKD reduces as eGFR 213 
declines, partly as the mode of CVD events in advanced CKD becomes less driven by atherosclerotic 214 
effects and more by heart failure and sudden cardiovascular death. Therefore, cholesterol-lowering 215 
treatments are recommended for primary prevention in all patients with non-dialysis dependent CKD 216 
who are over 50 years or any patient with CKD and diabetes33.  Similar arguments pertain to the 217 
treatment of blood pressure, which is a risk factor for both future CVD and CKD progression.  218 
Accurate documentation of kidney function should prompt consideration of whether to aim for lower 219 
blood pressure targets as informed by the SPRINT trial and its CKD subgroup analysis.34,35  Whilst the 220 
added NRI of 1.54% for CVD in this study seems modest, 1.37% more cases were appropriately 221 
identified which, when multiplied by how many people receive CVD risk scoring, would amount to a 222 
large number of people worldwide.  Indeed, in participants in the UK Biobank, addition of eGFRcys to 223 
atherosclerotic risk factors improves prediction and reclassification of CVD more substantially than 224 
does addition of total and HDL-C cholesterol to non-lipid atherosclerotic risk factors36.  Our results - 225 
showing eGFRcys as the most appropriate measure of renal function and predicting cardiovascular 226 
diseases - are therefore clinically important. eGFRcys should be incorporated into cardiovascular risk 227 
prediction tools.    228 
Supporting published data from other large cohort studies13,14,37, we have shown that eGFR is 229 
independently associated with CVD events and mortality, and CVD event rates were augmented as 230 
eGFR declined3.    Our conclusions assume a linear relationship between eGFR measures and 231 
outcome, in keeping with other published analyses14,21,37.  Both eGFRcys and eGFRcr demonstrated 232 
some increase in CVD, mortality and ESKD risk below 90 ml/min/1.73m2, however, there was 233 
pronounced flattening of the risk association across all outcomes for eGFRcr ~75-90 ml/min/1.73m2. 234 
eGFRcys demonstrated a much stronger, linear association with risk of mortality, CVD and ESKD 235 
10 
 
below eGFRcys 90 ml/min/1.73m2. Within the group with eGFRcys 60-89 ml/min/1.73m2, HRs for all-236 
cause mortality and both cardiovascular outcomes are mostly ~1.3 or higher, compared with HRs 237 
close to the reference for eGFRcr at the same level.  eGFRcys is therefore better suited for early 238 
detection of increased risk of these outcomes, both through its strong linear association, and a 239 
tendency to estimate lower GFR (and therefore higher risk).  Within our population, 37.5% had 240 
eGFRcr 60-89, increasing to 46.3% with eGFRcys.  This represents a substantial group of patients 241 
who could benefit from the added predictive value of eGFRcys - at relatively low cost of £2.50 (USD 242 
3.00) per test - particularly if used judiciously at point of CKD diagnosis or for one-off use in 243 
cardiovascular risk prediction tools.  The UK Biobank population may not be representative of the UK 244 
population with CKD G3-5 prevalence <2.0% by eGFRcr or ~4% by eGFRcys; across England, the 245 
prevalence of CKD G3-5 in adults is around 6.1%38.   Applied to a real-life population with a greater 246 
burden of kidney disease, the potential benefit of measuring eGFRcys for risk prediction may be 247 
augmented.   248 
In keeping with previous analyses from the Chronic Kidney Disease Prognosis Consortium 249 
(combining administrative datasets, observational cohorts and clinical trials)13,14,37, we have found 250 
albuminuria to be associated with mortality and cardiovascular events.  Our hazard ratios for all-cause 251 
mortality and fatal cardiovascular disease  were  broadly similar across uACR groups and eGFR 252 
categories to those found in a previous analysis from the Chronic Kidney Disease Prognosis 253 
Consortium14, though we report lower hazard ratios for fatal CVD for those with eGFR >45 and uACR 254 
>30mg/mmol, but higher HR for those with eGFR <45 and uACR >30mg/mmol than reported 255 
previously14. In contrast to previous studies, we did not find albuminuria to improve risk prediction 256 
over atherosclerotic risk factors and eGFRcys in reclassification models.  In the UK Biobank, only 257 
3.2% of 440,526 participants had uACR >30mg/mmol, compared to 11.5% of 105,715 participants 258 
representing the general population in the Chronic Kidney Disease Prognosis Consortium14.  259 
Furthermore, albuminuria was estimated from random spot urine samples, though early morning 260 
samples have been shown to correlate more closely with 24-hour urinary albumin concentration39.  261 
The risk associated with heavy albuminuria in our study may have been underestimated.   262 
  263 
11 
 
The strengths of this study lie in the large scale, prospective population-based cohort containing 264 
complete cases and a low proportion (0.06%) of excluded cases due to missing data.  The outcomes 265 
are obtained from linked health records and through self-reporting measures and therefore are likely 266 
to have captured the majority of hard endpoints of interest (CVD and death40). The data were 267 
obtained from a single-protocol study conducted in accordance with published protocols and 268 
measurement of biochemical data was centralised, affording consistent measurement of creatinine 269 
and cystatin C values used in the GFR calculators across all participants40.   270 
We acknowledge some weaknesses in the data presented.  Though the population studied was 271 
broadly representative of a real-life cohort (i.e. many had comorbidities including diabetes mellitus, 272 
hypertension and other comorbid disease), included participants were volunteers for the UK Biobank 273 
resource and therefore may not be representative of the breadth of comorbidity seen in the general 274 
population,41 particularly given the ~5% response rate.  Reflecting the general population, there was a 275 
relatively small proportion with advanced CKD (stages G4/5) and relatively few ESKD events.  eGFR 276 
measures may perform differently in later stage CKD, particularly with reference to prediction of 277 
ESKD, and this subgroup warrants more specific study.  Renal outcomes were identified from linked 278 
health records, but are more reliably obtained from designated renal resources such as the UK Renal 279 
Registry;42 renal outcomes were not linked to national registries and some ESKD outcomes may have 280 
been missed.  Similarly, cardiovascular endpoints obtained from linked health records will have 281 
captured most events, but these events have not been validated with the same rigour as in dedicated 282 
cardiovascular studies, and some cardiovascular endpoints may have been missed or incorrectly 283 
coded. The ethnic groups were representative of a UK population with a bias towards white ethnic 284 
groups.  We did not find eGFRcys to be predictive of CVD outcome in non-white ethnic groups, 285 
though with limited non-white participants it is difficult to draw any firm conclusions in other ethnic 286 
groups.  We have not adjusted for all cardiometabolic conditions associated with higher levels of 287 
cystatin C (including cancer, glucocorticoid therapy or thyroid disease), nor were participants with 288 
these conditions excluded.  Inclusion of participants with these conditions may have overestimated 289 
the impact of eGFRcys on outcome. Finally, GFR has been estimated from serum biomarkers and not 290 
measured using radioisotope studies, iohexol clearance or formal inulin clearance studies.  291 
Nevertheless, estimation of GFR is standard practice in the diagnosis of CKD. That noted, the size 292 
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and scope of UK Biobank means that our data particularly on CVD risk with eGFR data add strongly 293 
to this literature on this important question.  294 
In summary, we have shown that cystatin C-based calculations of GFR provide for more accurate 295 
prediction of all-cause mortality and fatal/non-fatal CVD. eGFRcys and albuminuria are independent 296 
risk factors for fatal/non-fatal CVD and should be considered in cardiovascular risk prediction to 297 
advise primary preventative treatment decisions. Consideration should be given to measuring serum 298 
cystatin C and using eGFRcys for diagnosis of CKD, prediction of CVD and thus making important 299 
clinical decisions around implementation of CVD risk lowering therapies in addition to conventional 300 
CVD risk factor calculators.  301 
Acknowledgements 302 
We would like to thank the participants of the UK Biobank.  The work in this study was supported by a 303 
grant from Chest, Heart and Stroke Association Scotland (Res16/A165).  J.S.L. has personal funding 304 
from a Kidney Research UK Training Fellowship Award (TF_013_20161125) and is supported by a 305 
British Heart Foundation Centre of Excellence Award (RE/13/5/30177).   306 
Author contributions 307 
J.S.L. and P.B.M. conceived of and designed the study.  Data were analysed by C.E.W. and P.W. 308 
under UK Biobank project 9310 led by N.S. and involving all authors.  The first draft of the manuscript 309 
was written by J.S.L. and C.E.W.  All authors (J.S.L., C.E.W., P.W., P.B.M., N.S., C.A.C-M., D.M., 310 
S.R.G., J.G.C., J.M.G., P.S.J., J.L., D.M.L., J.P.) read, critically revised and approved the final 311 
manuscript. 312 
Competing interests 313 
The authors declare no competing interests. 314 
13 
 
References (main text) 
1. Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C., et al. Global Prevalence of 
Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One 11 (7), 
e0158765 (2016). 
2. Evans, M., Grams, M. E., Sang, Y., Astor, B. C., Blankestijn, P. J., et al. Risk Factors for 
Prognosis in Patients With Severely Decreased GFR. Kidney Int. Reports 3, 625–637 (2018). 
3. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic Kidney Disease and 
the Risks of Death, Cardiovascular Events, and Hospitalization. N. Engl. J. Med. 351, 1296–
1305 (2004). 
4. Grams, M. E., Sang, Y., Ballew, S. H., Carrero, J. J., Djurdjev, O., et al. Predicting timing of 
clinical outcomes in patients with chronic kidney disease and severely decreased glomerular 
filtration rate. Kidney Int. 93, 1442–1451 (2018). 
5. Stauffer, M. E. & Fan, T. Prevalence of anemia in chronic kidney disease in the United States. 
Public Libr. Sci. one 9, (2014). 
6. Neri, L., Kreuzberg, U., Bellocchio, F., Brancaccio, D., Barbieri, C., et al. Detecting high-risk 
chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a 
historical cohort study. Nephrol. Dial. Transplant 34, 682–691 (2019). 
7. Levin, A., Bakris, G. L., Molitch, M., Smulders, M., Tian, J., et al. Prevalence of abnormal 
serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: 
Results of the study to evaluate early kidney disease. Kidney Int. 71, 31–38 (2007). 
8. Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., et al. Kidney Disease 
as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American 
Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure 
Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154–2169 
(2003). 
9. Israni, A. K., Snyder, J. J., Skeans, M. A., Peng, Y., MacLean, J. R., et al. Predicting coronary 
heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) 
14 
 
Study. Am J Transpl. 10, 338–353 (2010). 
10. Kasiske, B. L., Guijarro, C., Massy, Z. A., Wiederkehr, M. R., Ma, J. Z., et al. Cardiovascular 
disease after renal transplantation. J Am Soc Nephrol 7, 158–65 (1996). 
11. Kidney Disease Working Group. Kidney Disease: Improving Global Outcomes (KDIGO) 2012 
clinical practice guideline for the evaluation and management of chronic kidney disease. 
Kidney Int. 3, 1–150 (2013). 
12. Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., et 
al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and 
prevention. Lancet 382, 339–352 (2013). 
13. Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., et al. Estimated glomerular 
filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-
analysis of individual participant data. Lancet Diabetes Endocrinol. 3, 514–525 (2015). 
14. Matsushita, K., van der Velde, M., Astor, B. C., Woodward, M., Levey, A. S., et al. Association 
of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular 
mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 
(2010). 
15. Nitsch, D., Grams, M., Sang, Y., Black, C., Cirillo, M., et al. Associations of estimated 
glomerular filtration rate and albuminuria with mortality and renal failure by sex: A meta-
analysis. BMJ 346, 1–14 (2013). 
16. Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk 
prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort 
study. BMJ 357, j2099 (2017). 
17. Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., et al. 2016 European 
Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 37, 2315–
2381 (2016). 
18. Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., et al. 2013 
15 
 
ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college 
of cardiology/American heart association task force on practice guidelines. Circulation 129, 
(2014). 
19. Levey, A. A. S., Stevens, L. A. LA, Schmid, C. H., Zhang, Y. Y., Castro, A. 3rd A. F., et al. A 
New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 150, 604–612 (2009). 
20. Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., et al. Estimating 
glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367, 20–9 
(2012). 
21. Shlipak, M. G., Matsushita, K., Ärnlöv, J., Inker, L. A., Katz, R., et al. Cystatin C versus 
Creatinine in Determining Risk Based on Kidney Function. N. Engl. J. Med. 369, 932–943 
(2013). 
22. Shlipak, M. G., Mattes, M. D. & Peralta, C. A. Update on cystatin C: Incorporation into clinical 
practice. Am. J. Kidney Dis. 62, 595–603 (2013). 
23. National Institute for Health and Care Excellence & NICE. Costing statement: Chronic kidney 
disease Implementing the NICE guideline on chronic kidney disease (CG182). (2014). 
24. NICE. Chronic kidney disease in adults : assessment and management. NICE Guidel. (2018). 
25. Myers, G. L., Miller, W. G., Coresh, J., Fleming, J., Greenberg, N., et al. Recommendations for 
improving serum creatinine measurement: A report from the Laboratory Working Group of the 
National Kidney Disease Education Program. Clin. Chem. 52, 5–18 (2006). 
26. Zi, M. & Xu, Y. Involvement of cystatin C in immunity and apoptosis. Immunol. Lett. 196, 80–90 
(2018). 
27. Salgado, J. V., Souza, F. L. & Salgado, B. J. How to understand the association between 
cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? J. 
Cardiol. 62, 331–335 (2013). 
28. Van Diepen, M., Ramspek, C. L., Jager, K. J., Zoccali, C. & Dekker, F. W. Prediction versus 
aetiology: Common pitfalls and how to avoid them. Nephrol. Dial. Transplant. 32, ii1–ii5 (2017). 
16 
 
29. Lamb, E. J., Brettell, E. A., Cockwell, P., Dalton, N., Deeks, J. J., et al. The eGFR-C study: 
accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and 
albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease 
- prospective longitudinal study in a multiethnic. BMC Nephrol. 15, (2014). 
30. Tangri, N., Stevens, L., Griffith, J., Tighiouart, H., Djurdjev, O., et al. A Predictive Model for 
Progression of Chronic Kidney Disease to Kidney Failure. Jama 305, 1553 (2011). 
31. Herrington, W. G., Emberson, J., Mihaylova, B., Blackwell, L., Reith, C., et al. Impact of renal 
function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis 
of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 4, 829–
839 (2016). 
32. Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., et al. The effects of 
lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney 
disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 
377, 2181–2192 (2011). 
33. KDIGO. Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney 
Int. 3, 182–189 (2013). 
34. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-
Pressure Control. N. Engl. J. Med. 373, 2103–2116 (2015). 
35. Cheung, A. K., Rahman, M., Reboussin, D. M., Craven, T. E., Greene, T., et al. Effects of 
Intensive BP Control in CKD. J. Am. Soc. Nephrol. 28, 2812–2823 (2017). 
36. Welsh, C., Celis-Morales, C. A., Brown, R., Mackay, D. F., Lewsey, J., et al. Comparison of 
Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular 
Disease: Data from UK Biobank. Circulation (2019). 
doi:10.1161/CIRCULATIONAHA.119.041149 
37. Van Der Velde, M., Matsushita, K., Coresh, J., Astor, B. C., Woodward, M., et al. Lower 
estimated glomerular filtration rate and higher albuminuria are associated with all-cause and 
cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney 
17 
 
Int. 79, 1341–1352 (2011). 
38. National Cardiovascular Intelligence Network; Public Health England. Chronic kidney disease 
prevalence model. (2014). 
39. Witte, E. C., Lambers Heerspink, H. J., de Zeeuw, D., Bakker, S. J. L., de Jong, P. E., et al. 
First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria. 
J. Am. Soc. Nephrol. 20, 436–443 (2009). 
40. Elliott, P. & Peakman, T. C. The UK Biobank sample handling and storage protocol for the 
collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234–244 
(2008). 
41. Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., et al. Comparison of 
Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those 
of the General Population. Am. J. Epidemiol. 186, 1026–1034 (2017). 
42. Byrne, C., Caskey, F., Dawnay, C. C., Ford D, Lambie, F. S., et al. UK Renal Registry UK 
Renal Registry 19th Annual Report of the Renal Association. Nephron 137, (2017).   
18 
 
Figure legends 
Figure 1  
Fully adjusted splines of estimated glomerular filtration rate (eGFR) against adjusted hazard ratio 
(with 95% confidence limits) for all-cause mortality (top row), composite fatal/non-fatal cardiovascular 
disease (CVD) (second row) and fatal CVD (third row) using eGFR based on creatinine (eGFRcr; left 
column), eGFR based on cystatin C (eGFRcys; middle column) and eGFR based on creatinine and 
cystatin C (eGFRcr-cys; right column). 
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Figure 2 
Heat maps for prediction of all-cause mortality, composite fatal/non-fatal cardiovascular disease 
(CVD), fatal CVD and end-stage kidney disease using eGFRcys and albuminuria (urine 
albumin:creatinine ratio; uACR) for estimated glomerular filtration rate (eGFR) based on creatinine 
(eGFRcr; top), eGFR based on cystatin C (eGFRcys; middle) and eGFR based on creatinine and 
cystatin C (eGFRcr-cys; bottom). No data were available for those with eGFR >90ml/min/1.73m2 and 
uACR >3mg/mmol.  Otherwise, hazard ratios adjusted for atherosclerotic risk factors (age, sex, 
ethnicity, systolic and diastolic blood pressure, antihypertensive medications, statin use, smoking, 
diabetes, total and high-density lipoprotein cholesterol) were ranked 1-13 (1 being the lowest risk), 
and heat maps were colour-coded for all outcomes: 1-4 (green), 5-7 (yellow), 8-10 (orange), 11-13 
(red).  
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Figure 3  
Change in C-statistic with 95% confidence intervals for composite fatal/non-fatal cardiovascular 
disease, fatal cardiovascular disease or all-cause mortality upon addition of each estimated 
glomerular filtration rate (eGFR) method: eGFR based on creatinine (eGFRcr), eGFR based on 
cystatin C (eGFRcys) and eGFR based on creatinine and cystatin C (eGFRcr-cys). The centre line 
(0.00) represents no change to C-index.  
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Table 1 – Distribution of atherosclerotic risk factors by category of eGFRcr 
 
Baseline variables  eGFRcr range mL/min/1.73m2  
  >90 60-89 45-59 30-44 15-30 P value 
Number of participants 
 
267122 (60.6%) 165044 (37.5%) 7148 (1.6%) 991 (0.2%) 221 (0.1%)  
Age (years) 
 
54.15 (7.95) 59.21 (7.25) 62.59 (5.86) 62.82 (6.08) 60.76 (6.99) <0.001 
Sex Female 150134 (56.2%) 90057 (54.6%) 4222 (59.1%) 519 (52.4%) 95 (43.0%) <0.001  
Male 116988 (43.8%) 74987 (45.4%) 2926 (40.9%) 472 (47.6%) 126 (57.0%)  
Ethnicity White 250464 (93.8%) 158834 (96.2%) 6855 (95.9%) 943 (95.2%) 200 (90.5%) <0.001  
Black 5009 (1.9%) 1819 (1.1%) 70 (1.0%) 13 (1.3%) 9 (4.1%)   
South Asian 4850 (1.8%) 1752 (1.1%) 85 (1.2%) 16 (1.6%) 8 (3.6%)   
Other 6799 (2.5%) 2639 (1.6%) 138 (1.9%) 19 (1.9%) 4 (1.8%)  
Smoking status Non-smoker 233701 (87.9%) 151565 (92.3%) 6556 (92.4%) 891 (90.8%) 203 (92.7%) <0.001  
Smoker 32133 (12.1%) 12679 (7.7%) 542 (7.6%) 90 (9.2%) 16 (7.3%)  
Systolic blood pressure (mmHg) 
 
138.38 (19.47) 141.73 (19.76) 143.06 (19.99) 143.64 (20.35) 142.64 (20.53) <0.001 
Diastolic blood pressure (mmHg) 
 
82.26 (10.73) 82.71 (10.56) 81.84 (10.82) 80.27 (11.20) 78.95 (11.11) <0.001 
Antihypertensive medication No 227776 (85.3%) 129458 (78.4%) 3972 (55.6%) 302 (30.5%) 31 (14.0%) <0.001  
Yes 39346 (14.7%) 35586 (21.6%) 3176 (44.4%) 689 (69.5%) 190 (86.0%)  
Statins No 240373 (90.0%) 139578 (84.6%) 5041 (70.5%) 547 (55.2%) 99 (44.8%) <0.001  
Yes 26749 (10.0%) 25466 (15.4%) 2107 (29.5%) 444 (44.8%) 122 (55.2%)  
Self-reported diabetes mellitus at 
baseline  
No 
255049 (95.5%) 158240 (95.9%) 6407 (89.6%) 784 (79.1%) 158 (71.5%) <0.001  
Yes 12073 (4.5%) 6804 (4.1%) 741 (10.4%) 207 (20.9%) 63 (28.5%)  
Total cholesterol (mmol/l) 
 
5.75 (1.10) 5.79 (1.13) 5.58 (1.23) 5.29 (1.31) 4.93 (1.27) <0.001 
HDL cholesterol (mmol/l) 
 
1.47 (0.38) 1.46 (0.38) 1.39 (0.38) 1.30 (0.38) 1.28 (0.46) <0.001 
uACR (mg/mmol) <3 247449 (92.6%) 152917 (92.7%) 6099 (85.3%) 620 (62.6%) 68 (30.8%) <0.001  
3-30 11557 (4.3%) 6906 (4.2%) 648 (9.1%) 228 (23.0%) 65 (29.4%)   
>30 8116 (3.0%) 5221 (3.2%) 401 (5.6%) 143 (14.4%) 88 (39.8%)  
HBA1c (mmol/mol)  35.67 (6.77) 36.08 (5.61) 38.11 (7.69) 40.56 (10.83) 42.25 (12.74) <0.001 
Outcomes  
      
All-cause mortality No 259039 (97.0%) 158433 (96.0%) 6570 (91.9%) 844 (85.2%) 171 (77.4%) <0.001  
Yes 8083 (3.0%) 6611 (4.0%) 578 (8.1%) 147 (14.8%) 50 (22.6%)  
Composite CVD* No 262682 (98.3%) 161188 (97.7%) 6862 (96.0%) 928 (93.6%) 204 (92.3%) <0.001  
Yes 4440 (1.7%) 3856 (2.3%) 286 (4.0%) 63 (6.4%) 17 (7.7%)  
Fatal CVD** No 265868 (99.5%) 163918 (99.3%) 7022 (98.2%) 956 (96.5%) 210 (95.0%) <0.001  
Yes 1254 (0.5%) 1126 (0.7%) 126 (1.8%) 35 (3.5%) 11 (5.0%)  
End-stage kidney disease No 267064 (100.0%) 164976 (100.0%) 7110 (99.5%) 914 (92.2%) 126 (57.0%) <0.001 
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Yes 58 (<1%) 68 (<1%) 38 (0.5%) 77 (7.8%) 95 (43.0%)  
 
*Composite fatal/nonfatal cardiovascular disease (CVD) outcome as per American Heart Association/American College of Cardiology (AHA/ACC) risk score. 
**Fatal CVD outcome as per European Systematic Coronary Risk Evaluation (SCORE). CVD cardiovascular disease; HDL high-density lipoprotein; uACR 
urine albumin:creatinine ratio. 
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Table 2 - Adjusted* hazard ratios of each eGFR measure (per 10mL/min/1.73m2) for each of the 
four outcomes, among 440,526 UK Biobank participants. 
 N cases HR 
(per 10ml/ 
min/1.73m2) 
95% CI 1 SD HR  
(per 1 SD) 
95% CI 
All-cause mortality 15649      
eGFRcr   0.99 0.97-1.00 13.17 0.98 0.96-1.00 
eGFRcys  0.81 0.80-0.82 15.82 0.72 0.71-0.73 
eGFRcr-cys  0.84 0.82-0.85 12.66 0.80 0.78-0.81 
       
Composite CVD* 8662      
eGFRcr   0.95 0.93-0.97 13.17 0.93 0.91-0.96 
eGFRcys  0.87 0.86-0.88 15.82 0.80 0.78-0.82 
eGFRcr-cys  0.87 0.85-0.89 12.66 0.84 0.82-0.86 
       
Fatal CVD** 2552      
eGFRcr   0.92 0.89-0.95 13.17 0.90 0.86-0.94 
eGFRcys  0.77 0.75-0.79 15.82 0.66 0.63-0.69 
eGFRcr-cys  0.79 0.76-0.81 12.66 0.74 0.71-0.77 
       
End-stage kidney disease 336      
eGFRcr   0.33 0.31-0.35 13.17 0.23 0.21-0.25 
eGFRcys  0.29 0.28-0.31 15.82 0.14 0.13-0.16 
eGFRcr-cys  0.28 0.26-0.30 12.66 0.20 0.18-0.21 
 
*Adjusted for age, sex, ethnicity, systolic blood pressure, diastolic blood pressure, antihypertensive 
medications, smoking, diabetes, statin use, total and high-density lipoprotein (HDL) cholesterol.  
*Composite fatal/nonfatal cardiovascular disease (CVD) outcome as per American Heart 
Association/American College of Cardiology (AHA/ACC) risk score. **Fatal cardiovascular disease 
(CVD) outcome as per European Systematic Coronary Risk Evaluation (SCORE) 
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Table 3 – Net Reclassification Index for composite fatal/non-fatal CVD outcome for 3 eGFR 
measures: eGFRcr, eGFRcys and eGFRcr-cys 
 
Comparator Addition Case NRI 
(95%CI) 
Non-case NRI 
(95% CI) 
Atherosclerotic risk factors 
 
Atherosclerotic risk factors 
  
Atherosclerotic risk factors 
  
+eGFRcr  -0.08% 
(-0.41, +0.22%) 
-0.01% 
(-0.03, +0.01%) 
+eGFRcys 
 
+1.54% 
(+1.01, +2.10%) 
-0.17% 
(-0.21, -0.14%) 
+eGFRcr-cys +1.02% 
(+0.53, +1.48%) 
-0.11% 
(-0.14, -0.08%) 
Atherosclerotic risk factors +eGFRcr +uACR 
 
0.08% 
(-0.13, +0.19%) 
+0.01% 
(0.00, +0.02%) 
Atherosclerotic risk factors +eGFRcys  +uACR 
 
-0.03% 
(-0.15, +0.09%) 
+0.02% 
(0.01, +0.03%) 
Atherosclerotic risk factors +eGFRcr-cys
  
+uACR 
 
0.07% 
(-0.05, +0.18%) 
+0.01% 
(0.00, +0.02%) 
 
Estimated glomerular filtration rate (eGFR) method: eGFR based on creatinine (eGFRcr), eGFR 
based on cystatin C (eGFRcys) and eGFR based on creatinine and cystatin C (eGFRcr-cys). uACR 
urine albumin:creatinine ratio  
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Table 4 – Change in Harrell’s C-statistic for prediction of all-cause mortality, composite and 
fatal CVD outcomes and end-stage kidney disease in those with > 20% absolute discordance 
between eGFRcr and eGFRcys 
 
 N cases C-statistic Change in  
C-statistic 
P value 
All-cause mortality 6557/183867 0.7207 (0.7140-0.7275) na  
+ eGFRcr   0.7270 (0.7203-0.7337) 0.0063 (0.0042-0.0084) <0.001 
+ eGFRcys  0.7343 (0.7277-0.7410) 0.0136 (0.0108-0.0165) <0.001 
+ eGFRcr-cys  0.7246 (0.7178-0.7312) 0.0038 (0.0023-0.0054) <0.001 
     
Composite CVD 3565/183867 0.7422 (0.7338-0.7505) na  
+ eGFRcr   0.7425 (0.7341-0.7508) 0.0003 (-0.0003-0.0009) 0.347 
+ eGFRcys  0.7469 (0.7386-0.7552) 0.0047 (0.0027-0.0067) <0.001 
+ eGFRcr-cys  0.7448 (0.7365-0.7532) 0.0027 (0.0012-0.0042) <0.001 
     
Fatal CVD 1059/183867 0.7947 (0.7806-0.8088) na  
+ eGFRcr   0.7965 (0.7823-0.8107) 0.0018 (-0.0013-0.0049) 0.264 
+ eGFRcys  0.8036 (0.7897-0.8175) 0.0089 (0.0036-0.0141) 0.001 
+ eGFRcr-cys  0.7979 (0.7839-0.8119) 0.0032 (-0.0001-0.0065) 0.057 
     
ESKD 52/183867 0.7200 (0.6332-0.8068) na  
+ eGFRcr   0.7215 (0.6363-0.8067) 0.0015 (-0.0027-0.0058) 0.483 
+ eGFRcys  0.7301 (0.6378-0.8223) 0.0101 (-0.0473-0.0675) 0.730 
+ eGFRcr-cys  0.7446 (0.6649-0.8244) 0.0246 (-0.0337-0.0830) 0.408 
 
C-statistics and change in C-statistic for Cox proportional hazard models adjusted for atherosclerotic 
risk factors (age, sex, ethnicity, smoking, systolic and diastolic blood pressure, antihypertensive 
medications, statins, total and high-density lipoprotein (HDL) cholesterol) and log urine 
albumin:creatinine ratio (uACR) with addition of the three estimated glomerular filtration rate (eGFR) 
methods: eGFR based on creatinine (eGFRcr), eGFR based on cystatin C (eGFRcys) and eGFR 
based on creatinine and cystatin C (eGFRcr-cys). 
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Methods 
 
UK Biobank collected data from 502,536 consenting participants (age 37 to 73) from 2007-2010 
across 22 assessment centres in the UK.  Biological data and information from touch-screen 
questionnaires were collected at baseline as previously described.43,44 Ethical approval for UK 
Biobank was issued by the North West Multi-centre Research Ethics Committee (REC reference: 
11/NW/03820). The study was conducted in accordance with the principles of the Declaration of 
Helsinki, and all participants gave written informed consent before enrolment. 
 
Ethnicity was initially coded as white, black, south Asian or other, but for the purposes of eGFR 
calculators, ethnicity was coded as black or other.  Smoking history was self-reported and categorised 
as current/previous or never smoker.  We excluded those with prevalent ESKD or who were receiving 
renal replacement therapy in any form at baseline, defined from self-reported ESKD according to a 
pre-specified algorithm.45 We further excluded any participant with a calculated eGFR from any 
measure of <15 ml/min/1.73m2.  Participants with previous history of CVD (self-reported angina, 
myocardial infarction, stroke or transient ischaemic attack) were excluded.   
 
Full details of the biochemistry sampling, handling and quality control protocol for UK Biobank has 
been described and validated previously.40,46–48  In brief, blood and spot urine samples were collected 
and analysed at a central laboratory, including creatinine, cystatin C, lipids (high-density, low-density 
and total cholesterol) and urine albumin content (urine albumin:creatinine ratio; uACR).  The UK 
Biobank operated a high-turnover, clinic setup and thus samples were collected at various times of 
day.  Serum and urine creatinine were measured using an enzymatic (creatinase), IDMS-traceable, 
method on Beckman Coulter AU5400 instrument.49 Serum cystatin C was measured by latex 
enhanced immunoturbidimetric method on a Siemens ADVIA 1800 instrument.49 Urine microalbumin 
was measured by immunoturbidimetric method using reagents and calibrators sourced from Randox 
Bioscience (UK) 50.  Over 3 levels of control the coefficient of variation for creatinine was <2.8%48,for 
cystatin C, over 2 levels of control, was <1.4%48 and for urinary microalbumin and creatinine, over 2 
levels of control, was <2.1%50. Each assay was registered with an external quality assurance (EQA) 
scheme, and assay performance was externally verified via the results returned from participation in 
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these schemes. Data were adjusted by UK Biobank centrally before release to adjust for pre-
analytical variables51.  Estimated glomerular filtration rate was calculated by CKD-EPI using serum 
creatinine (eGFRcr)19, cystatin C (eGFRcys) or cystatin C-creatinine (eGFRcr-cys) equations as 
previously reported.20 
 
There were four outcomes of interest.  First, all-cause mortality was defined as death from any cause, 
with date and cause of death obtained from death certificates held by the National Health Service 
(NHS) Information Centre (participants in England and Wales) or the NHS Central Register Scotland 
(for participants from Scotland).  Second, composite fatal or non-fatal cardiovascular disease (CVD) 
events (nonfatal episodes of MI, stroke, or heart failure ICD10 codes I22, I24, I60, I61, I63 or I64, or 
fatal CVD ICD10 codes I20-I25, I60-I64) were identified by linkage with routine hospital data, and date 
and cause of death (where appropriate) were obtained from death certificates as for all-cause 
mortality.  Third, fatal CVD events were identified from fatal CVD ICD10 codes (I20-I25, I60-I64) and 
from death certificates as for all-cause mortality.  Last, ESKD was defined as reaching CKD stage G5 
or requirement for renal replacement therapy, using hospital admission ICD10 (E85.3, N16.5, N18.0, 
N18.5, Q60.1, T82.4, T86.1, Y60.2, Y61.2, Y62.2, Y84.1, Z49.0, Z49.1, Z49.2, Z94.0, Z99.2) and 
OPCS4 (L74.1, L74.2, L74.3, L74.4, L74.5, L74.6, L74.8, L74.9, M01.2, M01.3, M01.4, M01.5, M01.8, 
M01.9, M02.3, M08.4, M17.2, M17.4, M17.8, M17.9, X40.1, X40.2, X40.3, X40.4, X40.5, X40.6, 
X40.7, X40.8, X40.9, X41.1, X41.2, X41.8, X41.9, X42.1, X42.8, X42.9, X43.1) codes, or ICD10 codes 
(N18.0, N18.5) listed in any position in a death record, according to a pre-specified algorithm.45. 
 
The follow-up period started at the date of first assessment.  The follow-up period ended with the date 
of death, first date of hospitalisation for non-fatal CVD or ESKD, or end of follow-up (whichever 
occurred first).  For mortality endpoints, end of follow-up was recorded as the first of date of death, or 
the end of data collection for the attended assessment centre (30/11/2016 for centres in Scotland; 
31/1/2018 for centres in England/Wales).  
 
Statistical analysis 
Each eGFR was categorised into the following five groups (ml/min/1.73m2) aligned with KDIGO 
staging of chronic kidney disease: ≥90, 60-89, 45-59, 30-44, 15-30.11  The distributions of 
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atherosclerotic risk factors (age, sex, ethnicity, smoking, systolic and diastolic blood pressure, use of 
antihypertensive medication and statins, total and HDL cholesterol) and uACR were investigated 
across eGFR categories and across each outcome.  Continuous risk factors were displayed as mean 
(SD) if normally distributed and median (Q1-Q3) if skewed.  Categorical risk factors were displayed as 
count (%). Tests for trends across categories were performed using chi-squared tests, ANOVA or 
Wilcoxon rank-sum tests where appropriate. 
 
The event rate per 100,000 person years for each outcome in each category of eGFR was calculated 
using the Kaplan-Meier method, and the event-free survival rate per category was plotted using this 
method.   
 
Pearson correlation coefficients between the three linear eGFR measures were calculated.  To 
examine the relationship between each eGFR-outcome combination, restricted cubic splines (with 
knots at eGFR  of 20, 30, 45, 60, 75, 90, 105 and 115 ml/min/1.732) were constructed and each fully 
adjusted relationship (adjusted for age, sex, ethnicity, smoking, systolic and diastolic blood pressure, 
antihypertensive medications, statins, total and HDL cholesterol) was plotted.  
 
To assess the effect of the addition of each eGFR measure and albuminuria to the discriminative 
ability of atherosclerotic risk factors, Cox-proportional hazard models (adjusted as above) were 
constructed for all-cause mortality, fatal/non-fatal CVD or fatal CVD, and the change in model 
discrimination was assessed using Harrell’s C-statistics for each eGFR, in isolation and with addition 
of albuminuria.  To understand better the relationship between eGFR and each outcome in the 
context of different uACR levels, uACR was split into clinically meaningful groups (uACR <3, 3-30 or 
>30 mg/mmol according to the KDIGO clinical practice guideline for definition and classification of 
CKD11) and the hazard ratio for each category of eGFR within each uACR group was assessed. 
 
eGFR and albuminuria were modelled linearly, with log transformation for uACR.  Similar analyses 
were conducted in subgroups including gender, ethnicity (white vs. non-white), body mass index (<30, 
30-35, >35 kg/m2) and CKD 3b/4 (eGFRcr 15-45 ml/min/1.73m2).  As a sensitivity analysis, C-
statistics for change in model discrimination for each outcome in the group of participants with 
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eGFRcr <60ml/min/1.73m2, to check the influence of data linearity above 60ml/min/1.73m2, 
Categorical Net Reclassification Index was tested for reclassification of patients from “low” to 
“intermediate” risk, i.e. across the threshold 7.5% 10-year risk of CVD that would warrant initiation of 
statin therapy for CVD risk reduction.18 
 
As a sensitivity analysis we assessed cases in which there was > 20% absolute discordance between 
eGFRcr and eGFRcys.  Adjusted Cox-proportional hazard models (as above) were repeated for the 
group in which there was > 20% discordance for all 4 outcomes.  
 
We excluded participants with missing data and who reported baseline CVD or ESKD, or who had 
eGFR (any measure) <15 ml/min/1.72m2; all analyses were performed on complete cases. Analyses 
were performed using STATA 14 (StataCorp LP, College Station, USA) and nricens for R statistical 
software package (version 3.5.3) for NRI.  A p-value of <0.05 was considered statistically significant.  
Data availability 
The UK Biobank data that support the findings of this study are available from the UK Biobank 
(www.ukbiobank.ac.uk).  This study was conducted under project code 9310. 
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